Innovative drugs bring good news to obese patients

Recently, the Lancet Magazine EClinicalMedicine published a report by Chinese scholars about the glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR) dual agonist IBI362 in China for overweight or obese patients.
A randomized, placebo-controlled, multiple dose escalation phase Ib clinical study among subjects
.

The results of the study show that IBI362 is well tolerated in overweight or obese Chinese subjects, with significant weight loss and comprehensive benefits of metabolic characteristics
.

Demand for weight loss calls for innovative drugs

China is the country with the largest number of obese people in the world, and it is showing a gradual upward trend
.

"Obesity is a chronic disease that requires long-term treatment.
There is currently a lack of long-term effective and safe treatments
.

However, traditional weight loss drugs have limited weight loss effects and have certain safety issues
.

IBI362 is an innovative oxyntomodulin compound (OXM3) jointly promoted by Cinda Biopharmaceuticals and Eli Lilly.
It is the best-in-class glucagon-like peptide-1 (GLP-1) and glucagon Dual receptor agonist molecule
.

Studies have found that the effect of IBI362 is thought to be mediated by the binding and activation of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), which has a similar mechanism of action as OXM.
Therefore, it is expected to improve glucose tolerance and reduce body weight
.

In addition to the effects of GLP-1R agonists in promoting insulin secretion, lowering blood sugar and reducing weight, IBI362 may also increase energy consumption and improve liver fat metabolism through the activation of GCGR
.

Can bring multiple benefits

"This study is to evaluate the safety, tolerability, pharmacokinetic characteristics and efficacy of IBI362 in Chinese overweight or obese adults.
" Ji Linong
said, this is the first time to evaluate the weekly preparation GLP-1R/ in the Chinese population.

According to the researchers, the study included overweight (body mass index [BMI] ≥ 24 kg/m2) from 6 research centers with hyperphagia and/or at least one complication, or obesity (BMI ≥ 28 kg/m2).
m2) A total of 36 adult subjects were divided into 3 cohorts
.

Eligible subjects were randomized 2:1 in 3 dose-escalation cohorts to receive weekly subcutaneous injection of IBI362 or placebo for 12 weeks, and an additional 8 weeks of safety follow-up
.

The primary endpoint of the study is the safety and tolerability of IBI362, and the secondary endpoints include pharmacokinetics and pharmacodynamics, as well as changes in body weight, waist circumference, BMI, blood pressure and blood lipid levels from baseline
.

“Throughout the research process, the subjects, investigators, and research center personnel in charge of treating and evaluating subjects in each cohort remained blind to the allocation of treatment
.

The results show that in addition to the significant weight loss effect, IBI362 can also bring multiple metabolic features such as blood pressure, blood lipids, liver enzymes and blood uric acid
.

Still need to study in depth

"This is the first phase I clinical study of an innovative drug published in the Lancet series of journals in the field of metabolism in China.
The ability of clinical development has reached the international level, which is another milestone in the development of innovative drugs in the field of metabolic diseases in China
.
" The high-efficiency and multi-metabolic characteristics of the benefits reflect the advantages and potential of IBI362 as a new generation of GLP-1 drugs
.

What's more surprising is that further analysis of the study found that IBI362 can significantly reduce the blood uric acid level of obese subjects.
This is the world's first GLP-1R agonist drug with a significant decrease in blood uric acid level observed in early clinical studies
.

Qian Lei, Executive Director of the Medical Science and Strategic Special Diseases Department of Cinda Biopharmaceutical Group, expects that through hard work and solid clinical research and scientific development, we will actively promote the early listing of this innovative molecule, and strive to bring more benefits to obese patients as soon as possible.
Good treatment options
.

"I hope that IBI362, as a multi-target innovative drug, will show even more surprising results in subsequent phase II clinical studies in overweight/obese subjects.
" Ji Linong
said
.
(Source: Zhang Siwei, China Science News)

Related paper information: https://doi.
org/10.
1016/j.
eclinm.
2021.
101088